Cellectis Announces Board Changes Following Shareholders’ Meeting

Cellectis SA ( (CLLS) ) has provided an update.

On June 26, 2025, Cellectis held a shareholders’ meeting where approximately 57% of voting rights were exercised. The meeting resulted in the adoption of most resolutions and the appointment of Mr. André Muller to the Board of Directors, while Mr. Axel-Sven Malkomes’ term expired, and Mr. Pierre Bastid’s resignation became effective. The changes in the board are expected to bring valuable expertise to Cellectis, enhancing its strategic direction and operations in the biotechnology sector.

The most recent analyst rating on (CLLS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.

Spark’s Take on CLLS Stock

According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.

Cellectis SA’s overall stock score is primarily influenced by its financial performance challenges, particularly in profitability and efficiency. While technical indicators suggest some stability, negative valuation metrics due to net losses weigh heavily on the stock’s attractiveness.

To see Spark’s full report on CLLS stock, click here.

More about Cellectis SA

Cellectis is a clinical-stage biotechnology company that leverages its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company focuses on an allogeneic approach for CAR T immunotherapies in oncology, offering off-the-shelf and ready-to-use gene-edited CAR T-cells for cancer treatment. Cellectis is one of the few companies with in-house manufacturing capabilities, controlling the entire cell and gene therapy value chain. Headquartered in Paris, France, with locations in New York and Raleigh, NC, Cellectis is listed on the Nasdaq Global Market and Euronext Growth.

Average Trading Volume: 68,970

Technical Sentiment Signal: Sell

Current Market Cap: $107M

See more insights into CLLS stock on TipRanks’ Stock Analysis page.